New drug cocktail aims to starve pancreatic tumors
NCT ID NCT05034627
First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 39 times
Summary
This early-phase trial tests a combination of two drugs—calaspargase pegol-mknl and cobimetinib—in about 15 people with advanced pancreatic cancer that has spread. The goal is to find the safest dose and see how well the drugs work together to starve cancer cells by cutting off a key nutrient they need to grow. The study focuses on safety and tumor shrinkage, not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
Conditions
Explore the condition pages connected to this study.